Single Inhaler LABA/LAMA for COPD
Chronic obstructive pulmonary disease (COPD) is a common disabling disease characterized by progressive airflow obstruction. Great efforts were spent in the development of drugs able to improve symptoms, quality of life, reduce exacerbations, hospitalizations and the frequency of death of patients w...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00390/full |
id |
doaj-450c7dd009254660adbc632f38c73433 |
---|---|
record_format |
Article |
spelling |
doaj-450c7dd009254660adbc632f38c734332020-11-24T23:09:14ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-04-011010.3389/fphar.2019.00390431555Single Inhaler LABA/LAMA for COPDMario Malerba0Mario Malerba1Valentina Foci2Valentina Foci3Filippo Patrucco4Filippo Patrucco5Patrizia Pochetti6Patrizia Pochetti7Matteo Nardin8Corrado Pelaia9Alessandro Radaeli10Respiratory Medicine, Department of Translational Medicine, University of Eastern Piedmont, Vercelli, ItalyRespiratory Unit, Sant’Andrea Hospital, Vercelli, ItalyRespiratory Medicine, Department of Translational Medicine, University of Eastern Piedmont, Vercelli, ItalyRespiratory Unit, Sant’Andrea Hospital, Vercelli, ItalyRespiratory Medicine, Department of Translational Medicine, University of Eastern Piedmont, Vercelli, ItalyRespiratory Unit, Sant’Andrea Hospital, Vercelli, ItalyRespiratory Medicine, Department of Translational Medicine, University of Eastern Piedmont, Vercelli, ItalyRespiratory Unit, Sant’Andrea Hospital, Vercelli, ItalyDepartment of Medicine, Spedali Civili di Brescia, Brescia, ItalyDepartment of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia” of Catanzaro, Catanzaro, ItalyDepartment of Emergency, Spedali Civili di Brescia, Brescia, ItalyChronic obstructive pulmonary disease (COPD) is a common disabling disease characterized by progressive airflow obstruction. Great efforts were spent in the development of drugs able to improve symptoms, quality of life, reduce exacerbations, hospitalizations and the frequency of death of patients with COPD. The cornerstones of treatment are bronchodilator drugs of two different classes: beta agonists and muscarinic antagonists. Currently the Global initiative for COPD suggests the use of long acting beta agonists (LABAs) and long acting muscarinic antagonists (LAMAs) in combination for the majority of COPD patients, thus great interest is associated with the developing of LAMA/LABA fixed combination in the maintenance treatment of stable COPD. Many LAMA/LABA fixed dose combinations have been licensed in different countries and the clinical use of these drugs stimulated the performance of many clinical trials. The purpose of this review is a complete criticism of pharmacological and clinical aspects related to the use of LAMA/LABA single inhalers for the maintenance treatment of stable COPD, with particular mention to the most debated topics and future prospects in the field.https://www.frontiersin.org/article/10.3389/fphar.2019.00390/fullchronic obstructive pulmonary disease (COPD)LABALAMAmaintenance treatmentfixed dose combination (FDC) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mario Malerba Mario Malerba Valentina Foci Valentina Foci Filippo Patrucco Filippo Patrucco Patrizia Pochetti Patrizia Pochetti Matteo Nardin Corrado Pelaia Alessandro Radaeli |
spellingShingle |
Mario Malerba Mario Malerba Valentina Foci Valentina Foci Filippo Patrucco Filippo Patrucco Patrizia Pochetti Patrizia Pochetti Matteo Nardin Corrado Pelaia Alessandro Radaeli Single Inhaler LABA/LAMA for COPD Frontiers in Pharmacology chronic obstructive pulmonary disease (COPD) LABA LAMA maintenance treatment fixed dose combination (FDC) |
author_facet |
Mario Malerba Mario Malerba Valentina Foci Valentina Foci Filippo Patrucco Filippo Patrucco Patrizia Pochetti Patrizia Pochetti Matteo Nardin Corrado Pelaia Alessandro Radaeli |
author_sort |
Mario Malerba |
title |
Single Inhaler LABA/LAMA for COPD |
title_short |
Single Inhaler LABA/LAMA for COPD |
title_full |
Single Inhaler LABA/LAMA for COPD |
title_fullStr |
Single Inhaler LABA/LAMA for COPD |
title_full_unstemmed |
Single Inhaler LABA/LAMA for COPD |
title_sort |
single inhaler laba/lama for copd |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2019-04-01 |
description |
Chronic obstructive pulmonary disease (COPD) is a common disabling disease characterized by progressive airflow obstruction. Great efforts were spent in the development of drugs able to improve symptoms, quality of life, reduce exacerbations, hospitalizations and the frequency of death of patients with COPD. The cornerstones of treatment are bronchodilator drugs of two different classes: beta agonists and muscarinic antagonists. Currently the Global initiative for COPD suggests the use of long acting beta agonists (LABAs) and long acting muscarinic antagonists (LAMAs) in combination for the majority of COPD patients, thus great interest is associated with the developing of LAMA/LABA fixed combination in the maintenance treatment of stable COPD. Many LAMA/LABA fixed dose combinations have been licensed in different countries and the clinical use of these drugs stimulated the performance of many clinical trials. The purpose of this review is a complete criticism of pharmacological and clinical aspects related to the use of LAMA/LABA single inhalers for the maintenance treatment of stable COPD, with particular mention to the most debated topics and future prospects in the field. |
topic |
chronic obstructive pulmonary disease (COPD) LABA LAMA maintenance treatment fixed dose combination (FDC) |
url |
https://www.frontiersin.org/article/10.3389/fphar.2019.00390/full |
work_keys_str_mv |
AT mariomalerba singleinhalerlabalamaforcopd AT mariomalerba singleinhalerlabalamaforcopd AT valentinafoci singleinhalerlabalamaforcopd AT valentinafoci singleinhalerlabalamaforcopd AT filippopatrucco singleinhalerlabalamaforcopd AT filippopatrucco singleinhalerlabalamaforcopd AT patriziapochetti singleinhalerlabalamaforcopd AT patriziapochetti singleinhalerlabalamaforcopd AT matteonardin singleinhalerlabalamaforcopd AT corradopelaia singleinhalerlabalamaforcopd AT alessandroradaeli singleinhalerlabalamaforcopd |
_version_ |
1725610807878746112 |